FDA Approves Copper Histidinate for Menkes Disease: 78% Survival Benefit in Pediatric Patients

Executive Brief

News Report

The News: FDA approves Zycubo for Menkes disease, the first treatment for this rare pediatric condition.
Clinical Win: Zycubo offers a 78% reduction in mortality risk for early-treated pediatric patients.
Target Specialty: Neurology

Key Data at a Glance

FDA Approval Date: January 12, 2026
Risk Reduction in Mortality: 78%
Survival Beyond 6 Years: 50% of early-treated patients

The FDA announced on January 12, 2026, the approval of Zycubo (copper histidinate) as the first treatment for Menkes disease in pediatric patients. This approval is significant as it provides a much-needed therapeutic option for a devastating genetic disorder that severely affects copper absorption in children.

Clinical Context

Menkes disease is a rare neurodegenerative disorder caused by a genetic defect that impairs the body's ability to absorb copper, a vital mineral necessary for various bodily functions. Symptoms typically begin in infancy and include developmental delays, seizures, and failure to thrive, leading to severe complications and often resulting in death by age three. The condition affects approximately 1 in every 100,000 to 250,000 live births, predominantly in males. Current management options are limited, primarily focusing on supportive care, which often fails to address the underlying copper deficiency. The approval of Zycubo marks a pivotal moment in the management of Menkes disease, offering a copper replacement therapy that bypasses the genetic defect in intestinal absorption and allows the body to utilize copper more effectively.

Key Findings

The FDA approved Zycubo (copper histidinate) for the treatment of Menkes disease in pediatric patients as of January 12, 2026 [1].

The approval was based on data from two open-label, single-arm clinical trials involving 66 treated patients, where those who began treatment within four weeks of birth demonstrated a 78% reduction in the risk of death compared to untreated patients [1].

Nearly half of the early-treated patients survived beyond six years, with some living more than 12 years, whereas no patients in the untreated control group survived beyond six years [1].

Safety & Tolerability

Common side effects included infections, respiratory problems, seizures, vomiting, fever, anemia, and injection site reactions; monitoring for copper toxicity is recommended [1].

What This Means for Clinical Practice

The approval of Zycubo is a groundbreaking advancement for clinicians treating children with Menkes disease. It provides a viable treatment option that can significantly improve survival outcomes when initiated early. Clinicians should consider screening and diagnosing Menkes disease promptly to initiate treatment within the critical window of four weeks after birth, as this can dramatically influence patient survival and quality of life. The introduction of Zycubo may also prompt discussions about the need for increased awareness and education regarding this rare condition among healthcare providers to ensure timely intervention. As with any new treatment, ongoing monitoring for adverse effects and efficacy will be essential in clinical practice.

Clinical Perspective

Workflow: The introduction of Zycubo necessitates prompt screening and diagnosis of Menkes disease to optimize treatment timing.

Economics: This treatment may reduce long-term healthcare costs associated with managing severe complications of untreated Menkes disease.

Patient Outcomes: Improved survival rates and quality of life for pediatric patients with Menkes disease are expected with early intervention using Zycubo.

Dr. Vikram Patel, Neurology

References

FDA — FDA Approves First Treatment for Children With Menkes Disease

FDA Approves Copper Histidinate for Menkes Disease: 78% Survival Benefit in Pediatric Patients

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Related Articles

FDA Approves Ofatumumab and Natalizumab for High Efficacy in Multiple Sclerosis Treatment

FDA Approves Donanemab for Alzheimer: 27% Cognitive Decline Reduction

CGRP Inhibitors: Erenumab, Fremanezumab, Galcanezumab, and Atogepant for Migraine Prevention

Verified HCP Portal